BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...damage repair company Artios Pharma Ltd. hired Abid Ansari as CFO. The former CFO of Precision BioSciences...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...a new CFO. Abid Ansari will step down from his role as CFO of gene editing play Precision BioSciences Inc....
BioCentury | Dec 15, 2020
Deals

Prevail acquisition affords Lilly an ‘entry point’ in gene therapy, with more deals likely to follow

...three-target deal with non-CRISPR gene editing company Precision BioSciences Inc....
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

...Paul Bonanos, Associate Editor A deal with Lilly delivering $135 million up front will allow Precision BioSciences...
...NYSE:LLY) will pay $100 million up front and make a $35 million equity investment in Precision BioSciences Inc....
...a gene therapy targeting micro-dystrophin for the disorder.TARGETSHAO1 - Hydroxyacid oxidase 1 Paul Bonanos Eli Lilly and Co. Precision BioSciences Inc....
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...IPOs have had setbacks on clinical data; the other two being allogeneic CAR T play Precision Biosciences Inc....
BioCentury | Jul 10, 2020
Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

...while an eighth targets BCMA plus CD19. The three most advanced candidates are PBCAR269A from Precision BioSciences Inc....
...issued a refuse-to-file letter in May requesting more CMC information. Amanda Micklus, Senior Biopharma Analyst Allogene Therapeutics Inc. Precision BioSciences Inc. Celularity...
BioCentury | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

...data from the Phase II PATHFINDER trial of avapritinib. Precision tumbles on CAR T data Precision BioSciences Inc....
...Autologous T cell therapy against CD19 (KTE-X19, KTE-C19) avapritinib (blu-285) RP-L02, RP-L102 CPI-0610 Kite Pharma Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Precision BioSciences Inc. Principia...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...data this year, including the first-in-human trial of PBCAR0191, a CD19-targeted allogeneic CAR T from Precision BioSciences Inc....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific Inc. (NYSE:TMO). Genome editing company Precision BioSciences Inc....
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

...Medicine Inc. (NASDAQ:EDIT); Homology Medicines Inc. (NASDAQ:FIXX); Intellia Therapeutics Inc. (NASDAQ:NTLA); LogicBio Therapeutics Inc. (NASDAQ:LOGC); Precision Biosciences Inc....
...Inc. BlueRock Therapeutics L.P. Caribou Biosciences Inc. Casebia Therapeutics CRISPR Therapeutics AG Editas Medicine Inc. Homology Medicines Inc. Intellia Therapeutics Inc. LogicBio Therapeutics Inc. Precision BioSciences Inc. Royal...
Items per page:
1 - 10 of 52
BioCentury | Jan 15, 2021
Management Tracks

Frates joins ALS company Amylyx; plus Artios, Valneva, Viravaxx

...damage repair company Artios Pharma Ltd. hired Abid Ansari as CFO. The former CFO of Precision BioSciences...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...a new CFO. Abid Ansari will step down from his role as CFO of gene editing play Precision BioSciences Inc....
BioCentury | Dec 15, 2020
Deals

Prevail acquisition affords Lilly an ‘entry point’ in gene therapy, with more deals likely to follow

...three-target deal with non-CRISPR gene editing company Precision BioSciences Inc....
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

...Paul Bonanos, Associate Editor A deal with Lilly delivering $135 million up front will allow Precision BioSciences...
...NYSE:LLY) will pay $100 million up front and make a $35 million equity investment in Precision BioSciences Inc....
...a gene therapy targeting micro-dystrophin for the disorder.TARGETSHAO1 - Hydroxyacid oxidase 1 Paul Bonanos Eli Lilly and Co. Precision BioSciences Inc....
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...IPOs have had setbacks on clinical data; the other two being allogeneic CAR T play Precision Biosciences Inc....
BioCentury | Jul 10, 2020
Product Development

Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

...while an eighth targets BCMA plus CD19. The three most advanced candidates are PBCAR269A from Precision BioSciences Inc....
...issued a refuse-to-file letter in May requesting more CMC information. Amanda Micklus, Senior Biopharma Analyst Allogene Therapeutics Inc. Precision BioSciences Inc. Celularity...
BioCentury | Dec 10, 2019
Clinical News

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

...data from the Phase II PATHFINDER trial of avapritinib. Precision tumbles on CAR T data Precision BioSciences Inc....
...Autologous T cell therapy against CD19 (KTE-X19, KTE-C19) avapritinib (blu-285) RP-L02, RP-L102 CPI-0610 Kite Pharma Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Precision BioSciences Inc. Principia...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...data this year, including the first-in-human trial of PBCAR0191, a CD19-targeted allogeneic CAR T from Precision BioSciences Inc....
BioCentury | Sep 27, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

...president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific Inc. (NYSE:TMO). Genome editing company Precision BioSciences Inc....
BioCentury | Aug 27, 2019
Tools & Techniques

Gene editing companies say human germline editing ‘currently inappropriate’

...Medicine Inc. (NASDAQ:EDIT); Homology Medicines Inc. (NASDAQ:FIXX); Intellia Therapeutics Inc. (NASDAQ:NTLA); LogicBio Therapeutics Inc. (NASDAQ:LOGC); Precision Biosciences Inc....
...Inc. BlueRock Therapeutics L.P. Caribou Biosciences Inc. Casebia Therapeutics CRISPR Therapeutics AG Editas Medicine Inc. Homology Medicines Inc. Intellia Therapeutics Inc. LogicBio Therapeutics Inc. Precision BioSciences Inc. Royal...
Items per page:
1 - 10 of 52